University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Christopher C. Benz, MD

Christopher C. Benz, MD

Director, Cancer & Developmental Therapeutics Program, Buck Institute for Research on Aging

Cancer Center Program Memberships

Affiliate Member

Education

University of California, Los Angeles, B.S., 1968, Biochemistry
University of Michigan, Ann Arbor, M.D., 1972, Medicine
VGH/CCABC & UBC, Vancouver, B.C., Canada, 1972-1978, Int Med/Hem-Onc
Yale Univ. School of Med, New Haven, CT, 1978-79, Oncology

Selected Publications

  1. Kang T, Yau C, Wong CK, Sanborn JZ, Newton Y, Vaske C, Benz SC, Krings G, Camarda R, Henry JE, Stuart J, Powell M, Benz CC. A risk-associated Active transcriptome phenotype expressed by histologically normal human breast tissue and linked to a pro-tumorigenic adipocyte population. Breast Cancer Res 22: 81, 2020.
    View on PubMed
  2. Powell MJ, Dufault SM, Henry JE, Allison AC, Cora R, Benz CC. Pregnancy hypertension and a commonly inherited IGF1R variant (rs2016347) reduce breast cancer risk by enhancing mammary gland involution. Journal of Oncology, 2019.
    View on PubMed
  3. Scott GK, Yau C, Becker BC, Khateeb S, Mahoney SA, Jensen MB, Hann B, Cowen BJ, Pegan SD, Benz CC. Targeting mitochondrial proline dehydrogenase with a suicide inhibitor to exploit synthetic lethal interactions with p53 upregulation and glutaminase inhibition. Mol Cancer Ther. 393: 2312-2321, 2019.
    View on PubMed
  4. Yu NY, Iftimi A, Yau C, Tobin NP., van't Veer L, Hoadley KA, Benz CC, Nordenskjold B, Fornander T, Stal O, Czene K, Esserman LJ, Lindstrom LS, for the STO Trialists Group. Long-term survival and benefit from tamoxifen therapy for patients with Luminal A and Luminal B breast cancer. JAMA Oncology, Aug 8.
    View on PubMed
  5. Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, Shen R, Taylor AM, Cherniak AD, Thorsson V, Akbani R, Bowlby R, Wong CK, Wiznerowicz M, Sanchez-Vega F, Robertson AG, Schneider BG, Lawrence MS, Noushmehr H, Malta TM, Cancer Genome Atlas Research Network, Stuart JM, Benz CC, Laird PW. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell 173: 291-304, 2018.
    View on PubMed
  6. Liu J, Lichtenberg, T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, et al. and Cancer Genome Atlas Research Network. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell 173: 400-416, 2018.
    View on PubMed
  7. Wiley CD, Schaum N, Alimirah F, Lopez-Dominguez JA, Orjalo AV, Scott G, Desprez P-Y, Benz C, Davalos AR, Campisi J. Small-molecule MDM2 antagonists attenuate the senescence-associated secretory phenotype. Scientific Reports 8: 2410, 2018.
    View on PubMed
  8. Zhou Y, Zou H, Yau C, Zhao L, Hall SC, Drummond DC, Farr-Jones S, Park JW, Benz CC, Marks JD. Discovery of internalizing antibodies to basal breast cancer cells. Protein Engineering, Design, and Selection 31: 17-28, 2018.
    View on PubMed
  9. Powell MJ, von Behren J, Neuhausen S, Reynolds P, Benz, CC. Functional IGF1R variant predicts breast cancer risk in women with preeclampsia in California Teachers Study. Cancer Causes & Control 28: 1027-1032, 2017.
    View on PubMed
  10. Lindstrom LS, Yau C, Czene K, Thompson CK, Hoadley KA, van't Veer LJ, Balassanian R, Bishop JW, Carpenter PM, Chen Y-Y, Datnow B, Hasteh F, Krings G, Lin F, Zhang Y, Nordenskjold B, Stal O, Benz CC, Fornander T, Borowsky AD, Esserman LJ for the STO Trialists Group. Intra-tumor heterogeneity of the estrogen receptor and the long-term risk of fatal breast cancer. J Natl Cancer Inst., 2018.
    View on PubMed
  11. Esserman, LJ, Yau C, Thompson CK, van't Veer LJ, Borowsky AD, Hoadley KA, Tobin NP, Nordenskjold B, Fornander T, Stal O, Benz CC, Lindstrom LS. Molecular tools identify indolent breast cancers with ultra-low risk over two decades. JAMA Oncology 3: 1503-1510, 2017.
    View on PubMed
  12. Scott GK, Chu D, Kaur R, Malato J, Rothschild DE, Frazier K, Eppenberger-Castori S, Hann B, Park BH, Benz CC. ERpS294 is a biomarker of ligand or mutational ERa activation and a breast cancer target for CDK2 inhibition. OncoTarget 8: 83432-83445, 2016.
    View on PubMed
  13. Troester MA, Hoadley KA, D'Arcy M, Cherniack AD, Stewart C, Koboldt DC, Robertson AG, Mahurkar S, Shen H, Wilkerson MD, Sandhu R, Johnson NB, Allison K, Beck AH, Yau C, Bowen J, Sheth M, Hwang ES, Perou CM, Laird PW, Ding L, Benz CC. DNA defects, epigenetics, and gene expression in cancer-adjacent breast: a study from The Cancer Genome Atlas. NPJ-Breast Cancer 2: 16007, 2016.
    View on PubMed